Patents Examined by Jeanette M Lieb
-
Patent number: 11919932Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.Type: GrantFiled: January 3, 2023Date of Patent: March 5, 2024Assignees: THE UNIVERSITY OF TOKYO, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Kouji Matsushima, Satoshi Ueha, Shungo Deshimaru, Chang-Yu Chen, Shoji Yokochi, Yoshiro Ishiwata, Shiro Shibayama
-
Patent number: 11911442Abstract: Disclosed are methods of treating obesity or an obesity-related condition comprising administering an effective amount of soluble (pro)renin receptor (sPRR) to a subject that is obese or having an obesity-related condition. In some instances, obesity-related conditions can be, but are not limited to, steatosis, hyperglycemia, insulin resistance, chronic renal disease. Disclosed are methods of reducing body weight comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating fatty liver in a subject comprising administering an effective amount of sPRR to a subject in need thereof. Disclosed are methods of treating a fluid and electrolyte disorder comprising administering an effective amount of sPRR to a subject diagnosed with a fluid and electrolyte disorder.Type: GrantFiled: December 22, 2022Date of Patent: February 27, 2024Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventor: Tianxin Yang
-
Patent number: 11897970Abstract: The invention provides novel antibacterial compounds of formulae IA, IB and IC as defined herein. Optionally, the antibacterial compounds can be bonded to a delivery agent that is capable of bonding to one or more structures on a bacterial cell membrane. The invention also provides the use of such compounds in treating or preventing bacterial infections, and processes for their synthesis.Type: GrantFiled: March 9, 2018Date of Patent: February 13, 2024Assignee: THE UNIVERSITY OF LIVERPOOLInventors: Ishwar Singh, Edward Taylor
-
Patent number: 11897928Abstract: Conjugates for delivering an anti-cancer agent to nerve cells are provided. Conjugate compounds of the present disclosure according to certain embodiments include a compound having a protein, peptide or pepetidomimetic that binds selectively to a neurotrophin receptor, an anti-cancer agent and a linker that covalently bonds the anti-cancer agent to the protein, peptide or pepetidomimetic binds selectively to the neurotrophin receptor. Compositions and methods for delivering an anti-cancer agent selectively into nerve cells (e.g., in the treatment of optic pathway glioma) as well as indications such as perineural invasion and skin cancers are also described. Also provided are methods of making the anti-cancer conjugate compounds.Type: GrantFiled: July 17, 2019Date of Patent: February 13, 2024Assignee: Manzanita Pharmaceuticals, Inc.Inventors: Stephen B. Kahl, Constance A. McKee
-
Patent number: 11890319Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.Type: GrantFiled: January 18, 2018Date of Patent: February 6, 2024Assignee: VISTERRA, INC.Inventors: Zachary Shriver, Obadiah Joseph Plante, Kai Li, Karthik Viswanathan, James C. Delaney, Boopathy Ramakrishnan, Andrew M. Wollacott
-
Patent number: 11883428Abstract: Agents, kits, and methods that utilize oxygenation to prevent and/or treat infections caused by anaerobic microorganisms are provided. The agents, kits, and methods according to several embodiments utilize oxygenation in the intestinal lumen to prevent and/or treat infections caused by anaerobic bacteria. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.Type: GrantFiled: June 21, 2021Date of Patent: January 30, 2024Assignee: LPOXY THERAPEUTICS, INC.Inventor: Larry D. Sutton
-
Patent number: 11878996Abstract: Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.Type: GrantFiled: December 18, 2020Date of Patent: January 23, 2024Assignee: Massachusetts Institute of TechnologyInventors: Mark David Simon, Bradley L. Pentelute, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
-
Patent number: 11873474Abstract: Novel methods and apparatus are disclosed for cell culture and cell recovery. The methods and apparatus simplify the process of cell separation from media, minimize potential damage to gas permeable devices during fluid handling, and allow closed system automated cell culture and cell recovery from gas permeable devices.Type: GrantFiled: September 16, 2021Date of Patent: January 16, 2024Assignee: Wilson Wolf ManufacturingInventors: Daniel P. Welch, John R. Wilson
-
Patent number: 11866483Abstract: [Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.Type: GrantFiled: May 30, 2019Date of Patent: January 9, 2024Assignees: KanonCure, Inc., National University Corporation Tottori UniversityInventors: Yohei Kono, Noriko Itaba, Goshi Shiota
-
Patent number: 11858961Abstract: Ammonium cation detergents comprising a quaternary or tertiary ammonium cation can be used as detergents to denature proteins and are particularly useful in denaturing glycoproteins or glycopeptides prior to enzymatic deglycosylation. Ammonium cation detergents with sulfate or sulfonate anions are particularly useful.Type: GrantFiled: August 10, 2021Date of Patent: January 2, 2024Assignee: Agilent Technologies, Inc.Inventors: Michael J. Kimzey, Francis T. Haxo, Vaishali Sharma
-
Patent number: 11858970Abstract: The present disclosure provides an oligopeptide FTLE isolated from chili pepper seeds, and application thereof in preventing or treating cancer, the oligopeptide is isolated from chili pepper seeds and has an anti-tumor effect, and in particular, the oligopeptide can effectively inhibit the growth and metabolism of HepG2 cells, and has a good application prospect.Type: GrantFiled: February 14, 2023Date of Patent: January 2, 2024Assignee: CHINA AGRICULTURAL UNIVERSITYInventors: Liang Zhao, Xiaojun Liao, Fengzhang Wang, Yongtao Wang, Lei Rao
-
Methods of preparing pH-stabilized and heat-sterilized organ preservation and/or perfusion solutions
Patent number: 11849721Abstract: An organ preservation and/or perfusion solution for an isolated tissue or organ is provided. The solution comprises dextran, glucose, calcium ions, a buffer, and water, has a pH of 6.6 to 7.8, and is sterile based on having been subjected to heat sterilization. A method of preparing the solution also is provided. The method comprises combining dextran, glucose, calcium ions, buffer, and water to obtain an initial solution, adjusting the pH of the initial solution to 7.0 to 7.8 if needed, and subjecting the initial solution to heat sterilization, thereby obtaining the organ preservation and/or perfusion solution. A method of preserving and/or perfusing an isolated tissue or organ also is provided. A method for flushing, storage, and/or transportation of an isolated lung after removal from a donor in preparation for eventual transplantation into a recipient also is provided.Type: GrantFiled: March 18, 2022Date of Patent: December 26, 2023Assignee: XVIVO PERFUSION ABInventors: Anne-Li Sigvardsson, Elin Sjöqvist -
Patent number: 11844813Abstract: A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner; wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 ?M to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.Type: GrantFiled: December 20, 2018Date of Patent: December 19, 2023Assignees: ST. ANNA KINDERKREBSFORSCHUNG, UNIVERSITÄT FÜR BODENKULTUR WIENInventors: Michael Traxlmayr, Christian Obinger, Charlotte Brey, Manfred Lehner
-
Patent number: 11846631Abstract: The present invention provides a method for determining the effect of a drug on a mature cardiomyocyte. In some embodiments, the method comprises using transmembrane voltage and/or intracellular calcium data obtained from control immature cardiomyocytes and those that have been contacted with the drug to parameterize models of immature cardiomyocytes, then applying a maturation matrix to generate a mature cardiomyocyte model. The method is useful for, among other things, predicting whether a drug may have proarrhythmic properties and for determining whether a particular drug should be administered to a patient.Type: GrantFiled: February 1, 2019Date of Patent: December 19, 2023Assignee: ORGANOS, INC.Inventors: Aslak Tveito, Samuel Wall, Karoline Horgmo Jaeger
-
Patent number: 11834673Abstract: The invention relates to methods for generating multipotent mammary stern cells from isolated and cultured human breast luminal cells. The method comprises the steps: 1. isolating and growing normal differentiated cells in vitro; 2. treating the differentiated cells with either a conditioned medium from active fibroblasts or cytokine. The invention also relates to multipotent mammary stem cells, cultures of the multipotent stem cells, differentiated cells, tissues, organs derived from the culture multipotent stem cells isolated by the methods disclosed and therapeutic and other uses for those cells thereof.Type: GrantFiled: August 10, 2021Date of Patent: December 5, 2023Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTREInventors: Abdelilah Aboussekhra, Huda H. Al-Khalaf, Hazem Ghebeh
-
Patent number: 11826724Abstract: The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion.Type: GrantFiled: July 12, 2021Date of Patent: November 28, 2023Assignee: CytoSorbents CorporationInventors: Tamaz Guliashvili, Thomas Golobish, Maryann Gruda, Pamela O'Sullivan, Andrew Scheirer, Vincent Capponi, Phillip Chan, Wei-Tai Young
-
Patent number: 11827907Abstract: The invention relates to a method of increasing the yield of virus, virus particles, or viral vectors from host cells in a bioreactor. The invention provides a reproducible and robust method and system of determining and controlling the optimal time of infection of host cells using a correlation of process air parameters including Air flow, O2 flow, and respective trends thereof resulting in increased virus yield.Type: GrantFiled: May 19, 2022Date of Patent: November 28, 2023Assignee: RESILIENCE GOVERNMENT SERVICES, INC.Inventors: Perry Newton, Dalton Berrie, Tyler Grow, Sheldon Doxilly, Christopher J. Montoya, Sara Jane Terpening, Eric Vela
-
Patent number: 11826385Abstract: Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.Type: GrantFiled: November 10, 2018Date of Patent: November 28, 2023Assignee: Jura Bio, Inc.Inventors: Julie Norville, Elizabeth Wood
-
Patent number: 11820799Abstract: Compositions including an antibiotic factor from Malassezia are provided. In some examples, the compositions include a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell and a pharmaceutically acceptable carrier. Methods of treating an infection in a subject, such as a Staphylococcus infection are also provided.Type: GrantFiled: May 27, 2022Date of Patent: November 21, 2023Assignee: University of OregonInventors: Matthew Barber, Caitlin Kowalski
-
Patent number: 11813306Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.Type: GrantFiled: March 12, 2021Date of Patent: November 14, 2023Assignee: Novartis AGInventors: Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Liansheng Su, Lihua Yang, Rui Zheng